Paid Clinical Trials in Tucson

Dr. Ahmed Zayed

Written by Dr. Ahmed Zayed

Board-certified Physician | Graduate w/ Honors Faculty of Medicine | Alexandria, Egypt

Tucson City is nestled in the heart of Arizona, which boasts a dynamic environment for clinical research and innovation.

Clinical Research in Tucson 

Tucson is the place to be if you are passionate about contributing to medical progress. We are here to provide access to ongoing or future clinical trials in your local area. Together, we can make strides toward a healthier future.

Clinical Trials For Disease Areas in Tucson 

Science and research go hand-in-hand with a commitment to improving patient care. New developments in areas like orthopedics, soft tissue injuries, insomnia, sickle cell disease, genetic diseases, and other disorders have helped Tucson research centers provide the best quality care.

Research Corporation Technologies (RCT) in Tucson, Arizona, is one such company that specializes in technology investment. They fund promising biomedical ventures and academic innovations. They’ve invested more than $200 million to improve medical devices, create innovative therapeutics, and advance medical technology.

Quality Of Life Medical Research Center is another example of a renowned institution that strives to improve the well-being and overall health of patients. This research center has been working for more than 20 years and made notable contributions to the field of medicine. 

Their recent clinical trials have provided notable insight into different health problems. These trials include the Gout study, Covid 19 vaccine trials, low testosterone traverse study, and women’s health study on hypoactive sex drive.

We aim to ensure that every clinical trial gets enough volunteers to drive medical progress. With your help, we can make that dream a reality. Browse the list below, and apply for a clinical trial today!

Arizona Cancer Center Biospecimen Repository
Recruiting
RATIONALE: Collecting and storing samples of tissue and blood from patients with cancer to test in the laboratory may help the study of cancer in the future. PURPOSE: This research study is collecting and storing tumor, tissue, and blood samples from patients with pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2024
Locations: Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson, Arizona
Conditions: Cancer
Alzheimer's Disease Core Center
Recruiting
The main objective of this research project is to provide a comprehensive clinical database of patients with Alzheimer's disease (AD) and other forms of dementia, individuals with mild cognitive impairment (MCI), and age-matched normal controls. The study will also attempt to identify cognitively normal individuals at genetically defined risk for Alzheimer's disease through genetic screening. All participants are seen annually. Autopsies to establish diagnoses in patients with dementia, patient... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/10/2015
Locations: University of Arizona, University Medical Center, Tucson, Arizona
Conditions: Alzheimer's Disease, Mild Cognitive Impairment, Age-Related Memory Disorders
Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation
Recruiting
This study will evaluate the safety of infusion of the investigational cord blood units by carefully documenting all infusion-related problems.
Gender:
ALL
Ages:
All
Trial Updated:
04/17/2024
Locations: Children's of Alabama, Birmingham, Alabama
Conditions: Infusion Reactions
LOWER: Lomitapide Observational Worldwide Evaluation Registry
Recruiting
This global product exposure registry is a multicentre, long-term, prospective, observational cohort study (exposure registry), designed to evaluate the long term safety and effectiveness of lomitapide.
Gender:
ALL
Ages:
All
Trial Updated:
03/11/2024
Locations: Brookwood Baptist Medical Center, Birmingham, Alabama
Conditions: Homozygous Familial Hypercholesterolemia
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +1 locations
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Recruiting
A multicenter, open-label Phase 2b study of selinexor (KPT-330) in participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have no therapeutic options of demonstrated clinical benefit.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2024
Locations: UACC Arizona, Tucson, Arizona
Conditions: Diffuse Large B-cell Lymphoma
A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma
Recruiting
Primary Objective: To assess the activity of Afatinib in patients with persistent or recurrent uterine serous carcinoma overexpressing HER2/neu with the frequency of patients who survive progression-free for at least 6 months after initiating therapy. Secondary Objectives: To assess objective response rate and durable disease control rate. To assess overall survival. To assess the safety profile of Afatinib in uterine serous carcinoma patients.
Gender:
FEMALE
Ages:
Between 18 years and 100 years
Trial Updated:
08/16/2024
Locations: University of Arizona Cancer Center, Tucson, Arizona
Conditions: HER2/Neu+ Uterine Serous Carcinoma
Pharmacogenomics of Heparin-Induced Thrombocytopenia
Recruiting
The purpose of this research is to identify genomic markers that can predict heparin-induced thrombocytopenia (HIT), which is a very serious side effect to heparin. Heparin is commonly used to prevent blood clots and the investigators may be able to identify genomic markers which can be used to prevent heparin use in people who will get HIT.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2024
Locations: Banner University Medical Center - Tucson, Tucson, Arizona
Conditions: Heparin-induced Thrombocytopenia
An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis
Recruiting
The present study D5272C00001 (Legacy # 3151-201-008) seeks to evaluate the efficacy and safety of brazikumab versus placebo in patients with moderately to severely active UC and will include assessments of clinical responses as demonstrated by improvement of symptoms and of colonic mucosal appearance as observed on endoscopy.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
01/19/2021
Locations: Research Site, Tucson, Arizona
Conditions: Ulcerative Colitis
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: GSK Investigational Site, Goodyear, Arizona +1 locations
Conditions: Neoplasms

Want to know who pays for a clinical trial? 

Every paid clinical trial is unique. Many times, the company that creates the drug or medical device is the one that funds the clinical trial. At other times, government health organizations or research groups fund studies to find treatments or cures for specific illnesses. 

The sponsor can cover the costs of treatments like medicine or tests that are needed for the trial. The sponsor is also the one that often compensates volunteers for taking part in the clinical trial.

If you think about joining a clinical trial, consult with a doctor or specialist who will be working on that trial. They can give you some valuable insight into the compensation and any other expenses you might expect. This includes items such as medications, laboratory testing, imaging, hospital visits, overnight stays, etc.

Clinical Trials For Health Volunteers in Tucson 

As a health volunteer in Tucson, Arizona, you need to know exactly what you are getting yourself into. 

Clinical research is designed to help experts find new ways to treat or prevent diseases. The data collected helps answer questions about human behavior, body reactions, and therapy effects. 

Clinical trials can study new or existing treatments, drug combinations, less invasive procedures, and medical devices. But, they can also be focused on detecting lesser-known diseases and genetic complications. 

Clinical trials go through different phases. Each phase is meant to answer a specific question. For example, Phase 1 can help assess if the drug or treatment is safe. By the second phase, researchers can see if the drug works. The third phase is here to analyze whether the drug is better than the currently available medication. While Phase 4 looks at the potential long-term effects of the drug.

Check out the list below to find a clinical trial that suits your needs!

No trials could be found at this time

Medical Discoveries and Innovation in Tucson

Innovation has transformed the field of medicine in Tucson. Over the past five decades, we’ve seen the development of DNA testing, better cancer therapies, smart devices for blood sugar testing, and improved medical devices. 

Once deadly diseases have become treatable. Now, we are able to increase the lifespan of people with HIV and reduce the chances of infection.

In the 90s, available hepatitis C treatments only benefitted 10% of patients. This rate later rose to 50%, but patients had to follow a long 48-week regimen. Thankfully, by 2011, the FDA gave the green light to the first genuinely potent hepatitis C treatment capable of curing up to 90% of patients. 

Today, thanks to the UA College of Medicine, Tucson is at the forefront of research and innovation in precision medicine.   

Why Tucson Is A Great Place For Clinical Research 

Tucson has a predominantly White (45.5%) and Hispanic (42.1%) community. But, other races and ethnicities also live here, making it a great choice for clinical research. About 5% of its residents are Black, 3% are Asian, 2.4% are mixed, and 2% are Multiracial.